Haleon plc (HLN)vsZoetis Inc (ZTS)
HLN
Haleon plc
$8.95
+1.79%
HEALTHCARE · Cap: $39.55B
ZTS
Zoetis Inc
$75.89
-0.10%
HEALTHCARE · Cap: $33.36B
Smart Verdict
WallStSmart Research — data-driven comparison
Haleon plc generates 16% more annual revenue ($11.03B vs $9.53B). ZTS leads profitability with a 28.0% profit margin vs 15.1%. ZTS appears more attractively valued with a PEG of 1.91. ZTS earns a higher WallStSmart Score of 66/100 (B-).
HLN
Buy63
out of 100
Grade: C+
ZTS
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for HLN.
Margin of Safety
+11.5%
Fair Value
$145.45
Current Price
$75.89
$69.56 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 92.0% YoY
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 23.2%
Generating 1.3B in free cash flow
Every $100 of equity generates 82 in profit
Strong operational efficiency at 36.6%
Safe zone — low bankruptcy risk
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Areas to Watch
Expensive relative to growth rate
0.6% revenue growth
Grey zone — moderate risk
Expensive relative to growth rate
Trading at 9.7x book value
2.9% revenue growth
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : HLN
The strongest argument for HLN centers on EPS Growth, P/E Ratio, Price/Book. Profitability is solid with margins at 15.1% and operating margin at 23.2%.
Bull Case : ZTS
The strongest argument for ZTS centers on Return on Equity, Operating Margin, Altman Z-Score. Profitability is solid with margins at 28.0% and operating margin at 36.6%.
Bear Case : HLN
The primary concerns for HLN are PEG Ratio, Revenue Growth, Altman Z-Score.
Bear Case : ZTS
The primary concerns for ZTS are PEG Ratio, Price/Book, Revenue Growth. Debt-to-equity of 2.86 is elevated, increasing financial risk.
Key Dynamics to Monitor
ZTS carries more volatility with a beta of 0.74 — expect wider price swings.
ZTS is growing revenue faster at 2.9% — sustainability is the question.
HLN generates stronger free cash flow (1.3B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ZTS scores higher overall (66/100 vs 63/100), backed by strong 28.0% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Haleon plc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Haleon plc (HLN) is a prominent global consumer health company formed from a spin-off of GlaxoSmithKline, focusing on delivering innovative health solutions across a diverse portfolio of trusted brands, including Sensodyne, Panadol, and Voltaren. By concentrating on key segments such as oral care, pain relief, and dietary supplements, Haleon effectively addresses the dynamic needs of consumers while capitalizing on strong brand equity. The company's dedication to sustainability and relentless innovation, combined with strategic investments in product development, positions it advantageously for sustained long-term growth, thereby enhancing health outcomes and maximizing shareholder value.
Visit Website →Zoetis Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Zoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?